Eisai Licenses Kissei's Glufast For Southeast Asian Market
This article was originally published in PharmAsia News
Executive Summary
Eisai has signed a licensing agreement with Japanese pharmaceutical firm Kissei to develop and commercialize Kissei's Glufast (mitiglinide calcium hydrate) in 10 Southeast Asian countries, the companies announced June 12